Abbott Laboratories earnings call

… in international markets. I think that's only about 50% penetrated, so I think there's still a lot of opportunity to do the work that we're doing there. Obviously, scale and cost matter in the international markets, and I think we've got that position set. And then, you know, as you look at what I think is more specific to us, the opportunity to bring in a very differentiated product to look at market share shift in a segment that I'd say we're probably a little bit underrepresented from a market share perspective, which is on the pumper side, with the launch of our GKS sensor. I think that's going to provide us a great opportunity I'm not going to try and pinpoint the exact quarter here, Robbie, when we get approval. We'll issue the press release and we'll be out. But we've been working hard already, concomitantly, with the regulatory process, with KOLs, with physician groups, with payers. And I think there was an article that came out in the Lancet in January, beginning of this year, talking about the importance of measuring continuously ketones as DK is still a major care gap here for people with diabetes. So I think you've got a big opportunity here with this product for market share conversion. I think one of the surprising things for me in this as we started to really double click on these patient segments is, you know, we talked about the SGLT2 population. So we did some analysis in the U.S. You got about 6 million SGLT2 users in the U.S. And if you cross-reference their usage of CGM through all the databases, only about a million of those six are on CGMs. So I think there's going to be an opportunity here also to kind of create market expansion with this product. So not just share capture, but also market expansion. So this market is still very robust. It's becoming larger, so I get the law of big numbers kind of lowers those percentages, but if you just look at it from a penetration perspective, Robbie, there's still so much to do in all these segments and different geographies that we're still very excited and making big investments, whether it's in sales and marketing, clinical R&D and manufacturing, because we still think that this is still I'm not going to say it's the first or second inning, but we're far away from being from the seventh inning on this one. So I think there's still a lot of opportunity here, and we're in a good position.

… first generation products are and can we build those into Volt. And the feedback that I continue to see from the European market and quite frankly through the last couple of weeks as we began our limited market release here in the US is Two things keep jumping out pretty continuously is one, the elegance, the ease, and the smoothness, and the predictability of the mapping integrated with the catheter, the visualization, all of that that we spent a lot of time putting together. I continue to hear very positive feedback on that. You know, the ability to, you know, to potentially do these procedures with sedation versus general anesthesia, that is a recurring theme that I keep on hearing here. So I'd say the Volt launch has gone very much aligned to what we expected as we were putting the program together. This year we'll have the launch of Volt here in the U.S. and TactiFlex due internationally. I think it comes down to we always wanted to make sure that we had a toolbox approach here for the physicians. so they can have choice and they can have greater flexibility about how they use these products. I'm sure that there will be cases and types of patients and patient profiles that will lend itself more to a balloon and basket type design, and they're going to be types of patients in situations where PactiFlex Duo with its dual energy source will be preferred. And ultimately, it's going to be up to the physician to make those decisions, but I like the fact that you know, the team as they put the strategy together that we would have both these products. I think you raised, you know, you raised this point very well, which is I don't think that there is a company right now that's better positioned in terms of the completeness of the portfolio than what we have, you know, whether it's technology or the scale and the infrastructure starting with, you know, the capital placements that we've got, the incredibly, you know, competent clinical specialists that we have out in the field that have shown their value to our customers right now. We've got both RF and PFA products. We've got all the diagnostic elements, whether it's catheters, patches, et cetera, introducer sheets, all of that that you reference. And on top of that, we've got an LEA device, which is, I would say, is becoming pretty clear that if you want to be a leader in this space, you can't just look at …